Categories: HealthcareNews

Avantor® to Participate in 44th Annual J.P. Morgan Healthcare Conference

RADNOR, Pa., Jan. 5, 2026 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Emmanuel Ligner, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at approximately 8:15 a.m. Pacific Standard Time.

To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor’s website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days.

About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedInX (Twitter) and Facebook.

Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
Avantor
908-329-7281
Allison.Hosak@avantorsciences.com

Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-to-participate-in-44th-annual-jp-morgan-healthcare-conference-302647214.html

SOURCE Avantor and Financial News

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

5 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

8 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

8 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

8 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

8 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

8 hours ago